558 related articles for article (PubMed ID: 19267726)
21. Chemoradiotherapy: emerging treatment improvement strategies.
Milas L; Mason KA; Liao Z; Ang KK
Head Neck; 2003 Feb; 25(2):152-67. PubMed ID: 12509799
[TBL] [Abstract][Full Text] [Related]
22. Amifostine: the first selective-target and broad-spectrum radioprotector.
Kouvaris JR; Kouloulias VE; Vlahos LJ
Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
[TBL] [Abstract][Full Text] [Related]
23. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
25. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
[TBL] [Abstract][Full Text] [Related]
26. A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.
Fortin A; Caouette R; Wang CS; Vigneault E
Am J Clin Oncol; 2008 Aug; 31(4):379-83. PubMed ID: 18845998
[TBL] [Abstract][Full Text] [Related]
27. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
[TBL] [Abstract][Full Text] [Related]
28. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
[TBL] [Abstract][Full Text] [Related]
29. Current and emerging standards of concomitant chemoradiotherapy.
Adelstein DJ; Rodriguez CP
Semin Oncol; 2008 Jun; 35(3):211-20. PubMed ID: 18544436
[TBL] [Abstract][Full Text] [Related]
30. Does concurrent postoperative radiotherapy and chemotherapy in head and neck cancer improve patient outcome?
Yom SS; Rosenthal DI
Nat Clin Pract Oncol; 2004 Nov; 1(1):14-5. PubMed ID: 16264790
[No Abstract] [Full Text] [Related]
31. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
32. RADPLAT: an alternative to surgery?
Alkureishi LW; de Bree R; Ross GL
Oncologist; 2006 May; 11(5):469-80. PubMed ID: 16720847
[TBL] [Abstract][Full Text] [Related]
33. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
McCumber LM
Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
[TBL] [Abstract][Full Text] [Related]
34. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Nagy P; Kádasi L
Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
[TBL] [Abstract][Full Text] [Related]
35. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
36. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
37. Clinical trial design limitations in head and neck squamous cell carcinomas.
Yun HJ; Bogaerts J; Awada A; Lacombe D
Curr Opin Oncol; 2007 May; 19(3):210-5. PubMed ID: 17414638
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
39. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL; Oster W
Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
[TBL] [Abstract][Full Text] [Related]
40. Alternate delivery route for amifostine as a radio-/chemo-protecting agent.
Praetorius NP; Mandal TK
J Pharm Pharmacol; 2008 Jul; 60(7):809-15. PubMed ID: 18549666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]